Monday, August 20, 2012
Convertible debt investors are
hungry for paper and biotechs are eager to capitalize on this - even those
without marketed products and substantial revenues.
Over the last decade, biotechs
with sizable and growing revenues have primarily been the ones using
convertible notes. It has been more difficult for development stage companies,
which have to refinance debt if investors can't convert.